Table 3.
Univariate analysis of seroprotection rates by patients' characteristics for H1N1, H3N2, B strains.
| Patients with seroprotection before and after vaccination | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| H1N1 |
H3N2 |
B |
|||||||
| Factor | Before: n (%) | After: n (%) | Post vs Pre, p= | Before: n (%) | After: n (%) | Post vs Pre, p= | Before: n (%) | After: n (%) | Post vs Pre, p= |
| Age (years) | |||||||||
| ≤9 | 22/40 (55.0) | 30/40 (75.0) | 0.008 | 18/40 (45.0) | 25/40 (62.5) | 0.016 | 10/40 (25.0) | 18/40 (45.0) | 0.008 |
| >9 | 17/35 (48.6) | 29/35 (82.9) | <0.001 | 19/35 (54.3) | 31/35 (88.6) | <0.001 | 19/35 (54.3) | 26/35 (74.3) | 0.016 |
| (≤9 Vs 9) p= | ns | ns | ns | 0.0155 | 0.0168 | 0.0181 | |||
| Gender | |||||||||
| Male | 21/38 (55.3) | 33/38 (86.8) | <0.001 | 17/38 (44.7) | 30/38 (78.9) | <0.001 | 14/38 (36.8) | 24/38 (63.2) | 0.002 |
| Female | 18/37 (48.6) | 26/37 (70.3) | 0.008 | 20/37 (54.1) | 26/37 (70.3) | 0.031 | 15/37 (40.5) | 20/37 (54.1) | ns |
| (Male Vs Female) p= | ns | ns | ns | ns | ns | ns | |||
| Cancer type | |||||||||
| Hematological (Hem) | 26/53 (49.1) | 39/53 (73.6) | <0.001 | 22/53 (41.5) | 35/53 (66.0) | <0.001 | 16/53 (30.2) | 25/53 (47.2) | 0.004 |
| Solid | 13/22 (59.1) | 20/22 (90.9) | 0.016 | 15/22 (68.2) | 21/22 (95.5) | 0.031 | 13/22 (59.1) | 19/22 (86.4) | 0.031 |
| (Hem Vs Solid) p= | ns | ns | 0.0445 | 0.0079 | 0.0357 | 0.0019 | |||
| Treatment | |||||||||
| On | 34/62 (54.8) | 50/62 (80.6) | <0.001 | 32/62 (51.6) | 47/62 (75.8) | <0.001 | 23/62 (37.1) | 36/62 (58.1) | <0.001 |
| Off | 5/13 (38.5) | 9/13 (69.2) | ns | 5/13 (38.5) | 9/13 (69.2) | ns | 6/13 (46.2) | 8/13 (61.5) | ns |
| (On Vs Off) p= | ns | ns | ns | ns | ns | ns | |||
| Type of Treatment | |||||||||
| Intensive (Int) | 17/29 (58.6) | 24/29 (82.8) | 0.016 | 16/29 (55.2) | 25/29 (86.2) | 0.004 | 14/29 (48.3) | 20/29 (69.0) | 0.031 |
| Less intensive | 17/33 (51.5) | 26/33 (78.8) | 0.004 | 16/33 (48.5) | 22/33 (66.7) | 0.031 | 9/33 (27.3) | 16/33 (48.5) | 0.016 |
| (Int Vs Less Int) p= | ns | ns | ns | ns | ns | ns | |||
| Doses | |||||||||
| One | 26/51 (51.0) | 38/51 (74.5) | <0.001 | 26/51 (51.0) | 41/51 (80.4) | <0.001 | 20/51 (39.2) | 32/51 (62.7) | <0.001 |
| Two | 13/24 (54.2) | 21/24 (87.5) | 0.008 | 11/24 (45.8) | 15/24 (62.5) | ns | 9/24 (37.5) | 12/24 (50.0) | ns |
| (One Vs Two) p= | ns | ns | ns | ns | ns | ns | |||
| Lymphocytes (/mm3) | |||||||||
| ≤1000 | 11/21 (52.4) | 13/21 (61.9) | ns | 12/21 (57.1) | 16/21 (76.2) | ns | 8/21 (38.1) | 11/21 (52.4) | ns |
| >1000 | 28/51 (54.9) | 44/51 (88.2) | <0.001 | 25/51 (49.0) | 38/51 (74.5) | <0.001 | 19/51 (37.3) | 31/51 (60.8) | <0.001 |
| (≤1000 Vs >1000) p= | ns | 0.0480 | ns | ns | ns | ns | |||
| Sampling Time | |||||||||
| ≤45 | 19/35 (54.3) | 31/35 (88.6) | <0.001 | 16/35 (45.7) | 26/35 (74.3) | 0.002 | 11/35 (31.4) | 21/35 (60.0) | 0.002 |
| >45 | 20/40 (50.0) | 28/40 (70.0) | 0.008 | 21/40 (52.5) | 30/40 (75.0) | 0.004 | 18/40 (45.0) | 23/40 (57.5) | ns |
| (≤45 Vs >45) p= | ns | ns | ns | ns | ns | ns | |||
Data are number (percentage) of patients,ns: non significant,
*
at the time of vaccination,
**
time between final vaccination and collection of second sample,for 3 patients, lymphocytes count was missing.